Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD
KF Rabe, FJ Martinez, GT Ferguson… - … England Journal of …, 2020 - Mass Medical Soc
Background Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive …
Once-daily single-inhaler triple versus dual therapy in patients with COPD
DA Lipson, F Barnhart, N Brealey… - … England Journal of …, 2018 - Mass Medical Soc
Background The benefits of triple therapy for chronic obstructive pulmonary disease (COPD)
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long …
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary …
GT Ferguson, KF Rabe, FJ Martinez… - The Lancet …, 2018 - thelancet.com
Background Inhaled corticosteroids have been used in patients with chronic obstructive
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
pulmonary disease (COPD), but the potential benefits of their use in triple therapy are not …
Withdrawal of inhaled glucocorticoids and exacerbations of COPD
H Magnussen, B Disse… - … England Journal of …, 2014 - Mass Medical Soc
Background Treatment with inhaled glucocorticoids in combination with long-acting
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …
bronchodilators is recommended in patients with frequent exacerbations of severe chronic …
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
L Vanfleteren, LM Fabbri, A Papi… - … journal of chronic …, 2018 - Taylor & Francis
Recently, two “fixed triple” single-inhaler combinations of an inhaled corticosteroid (ICS), a
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have …
Triple therapy trials in COPD: a precision medicine opportunity
S Suissa, A Ariel - European Respiratory Journal, 2018 - Eur Respiratory Soc
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind …
D Singh, A Papi, M Corradi, I Pavlišová, I Montagna… - The Lancet, 2016 - thelancet.com
Background Few data are available for the efficacy of" triple therapy" with two long-acting
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary disease …
Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study
Introduction Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ ICS)
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational …
C Janson, K Larsson, KH Lisspers, B Ställberg… - Bmj, 2013 - bmj.com
Objective To investigate the occurrence of pneumonia and pneumonia related events in
patients with chronic obstructive pulmonary disease (COPD) treated with two different fixed …
patients with chronic obstructive pulmonary disease (COPD) treated with two different fixed …